Lumos Pharma Announced Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual Meeting
14 9월 2023 - 9:00PM
Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company
advancing an oral therapeutic candidate for moderate Pediatric
Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials,
announced today that an abstract reviewing interim data from its
OraGrowtH212 Trial has been accepted for oral presentation at the
2023 annual meeting of the European Society for Paediatric
Endocrinology, to be held in The Hague, Netherlands, September
21-23, 2023.
The abstract, Deconvolution Analysis: GH
secretagogue (LUM-201) enhances growth in individuals with moderate
idiopathic Pediatric Growth Hormone Deficiency (iPGHD) by enhancing
endogenous GH secretion and increasing IGF-1 (Fernando Cassorla,
MD, et al), will be presented in a late breaking session, Saturday,
September 23, 9:30-10:30 AM CET (Local Time).
About PGHD and the Therapeutic Landscape
PGHD is the consequence of inadequate secretion
of growth hormone from the pituitary gland in children resulting in
low growth hormone (GH) in the body, insufficient production of
downstream signaling molecules required for growth, and the
subsequent lack of growth. The prevailing standard of care for PGHD
consists of a daily injection of exogenous GH administered for
approximately 7 years on average. Several once-weekly injectable GH
therapies have recently been approved in the US and internationally
to treat PGHD. LUM-201, also known as ibutamoren, is an orally
administered investigational small molecule that promotes the
secretion of GH from the pituitary gland and represents an
opportunity for appropriately selected patients to avoid the daily
or weekly injections involved with current or forthcoming
therapies. LUM-201 has been observed to increase the amplitude of
endogenous pulsatile GH secretion, which mimics the natural pattern
of GH secretion.
About Lumos Pharma
Lumos Pharma, Inc. is a clinical stage
biopharmaceutical company focused on the development and
commercialization of therapeutics for rare diseases. The Company
was founded and is led by a management team with longstanding
experience in rare disease drug development. Lumos Pharma’s lead
therapeutic candidate, LUM-201, is a novel, oral growth hormone
(GH) secretagogue, seeking to transform the $4.5B global GH market
from injectable to oral therapy. LUM-201 is currently being
evaluated in multiple Phase 2 clinical studies in Pediatric Growth
Hormone Deficiency (PGHD) and has received Orphan Drug Designation
in both the US and EU. For more information, please visit
https://lumos-pharma.com/.
Investor & Media Contact:
Lisa MillerLumos Pharma Investor
Relations512-792-5454ir@lumos-pharma.com
Lumos Pharma (NASDAQ:LUMO)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Lumos Pharma (NASDAQ:LUMO)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024